Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH-E2: SCRT + CAPOX + Toripalimab vs LCRT + CAPOX for Early Low-lying Rectal Cancer
NCT06462053Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in rectal cancer, sponsored by Fudan University. Started Apr 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06462053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462053.